Why Cannabis Stocks Fizzled After the Rescheduling Announcement

The Rally That Lasted Hours, Not Days

On April 22, 2026, cannabis stocks erupted. Tilray surged from roughly $7 to $8 per share in a matter of hours. The AdvisorShares Pure US Cannabis ETF (MSOS) popped double digits. Multi-state operators like Curaleaf and Green Thumb saw their shares jump as traders piled into the sector on news that the Department of Justice was finally moving cannabis from Schedule I to Schedule III.

By the end of the week, almost all of those gains had evaporated. Tilray drifted back toward $6. MSOS surrendered its rally. The classic Wall Street pattern had played out once again: buy the rumor, sell the news. But in the cannabis sector, the disappointment ran deeper than typical profit-taking. Investors realized the rescheduling they'd been dreaming about for years wasn't quite the rescheduling they'd imagined.

The Narrow Scope Problem

The DOJ's April 23 final order reclassified cannabis to Schedule III, but with significant limitations that caught many investors off guard. The rescheduling applies specifically to FDA-approved marijuana products and products containing marijuana subject to a qualifying state-issued license — meaning state-legal medical cannabis programs. It does not broadly legalize adult-use cannabis at the federal level.

For the multi-state operators that dominate U.S. cannabis portfolios, this distinction matters enormously. Companies operating in recreational markets — which account for the majority of legal cannabis revenue in the United States — don't automatically benefit from the rescheduling in the ways investors initially assumed.

The immediate impact is real but narrower than headline writers suggested. Medical cannabis operations gain clearer federal standing, and the regulatory pathway for pharmaceutical cannabis products becomes more straightforward. But the sweeping market transformation that would come with full federal legalization or descheduling remains elusive.

The 280E Silver Lining

The most concrete financial benefit of rescheduling is the elimination of Section 280E of the Internal Revenue Code from cannabis operators' tax burdens. Under 280E, businesses trafficking in Schedule I or II controlled substances were prohibited from deducting ordinary business expenses from their federal taxes — a punishing provision that effectively doubled or tripled the tax rates of cannabis companies compared to normal businesses.

With cannabis moved to Schedule III, 280E no longer applies. For publicly traded multi-state operators, this translates to meaningfully improved after-tax profitability. Companies that were paying effective federal tax rates of 70 percent or higher will see those rates normalize to levels comparable with other industries.

Analysts estimate that the 280E elimination alone could add 10 to 20 percentage points of margin improvement for the largest operators, representing hundreds of millions of dollars in aggregate savings across the industry. That's a genuine, material benefit — but it's an accounting improvement, not a market expansion catalyst, and the market had largely priced it in during years of anticipation.

Why Fundamentals Haven't Changed Fast Enough

Beyond the rescheduling scope, several structural headwinds continue to weigh on cannabis equities. U.S. regulated cannabis revenues for 2025 came in between $29.1 and $29.6 billion, representing the first-ever annual year-over-year revenue decline for the legal market. Price compression from oversupply and intense competition has squeezed margins across the industry.

Cannabis retailers relied heavily on discounts and promotions to move product throughout 2025, with markdowns becoming a standard sales tactic rather than an occasional incentive. Wholesale flower prices have cratered in many markets, and even premium brands have felt the pressure to compete on price rather than differentiation.

These operational challenges don't disappear because of a rescheduling order. Companies still face fragmented state markets, limited access to institutional banking, restrictions on interstate commerce, and the persistent competition from illicit operators who don't bear the regulatory costs of legal compliance.

What Smart Money Is Watching

Institutional investors and analysts who follow the sector closely have adopted a more measured outlook. The consensus view treats 2026 as a year of gradual fundamental improvement rather than a speculative moonshot.

The most closely watched catalyst beyond 280E relief is the DEA's upcoming administrative hearing, set to begin June 29, 2026. This hearing could further clarify the regulatory framework and potentially expand the scope of rescheduling benefits. All interested parties must file their intent to participate by late May.

Banking reform remains the other major prize. While rescheduling reduces some friction with financial institutions, cannabis companies still face significant barriers to accessing traditional banking services, capital markets, and payment processing. Full banking normalization would require either additional federal legislation or further regulatory evolution.

The Long View for Cannabis Investors

For long-term investors, the post-rally pullback may represent an opportunity rather than a warning. The fundamental tax benefit of 280E elimination is real and will flow through financial statements over the coming quarters. Companies with strong balance sheets, efficient operations, and dominant market positions in key states are positioned to benefit most from the improved profitability environment.

However, cannabis remains a market for patient capital. The sector has repeatedly punished traders who chase headline-driven spikes without examining the underlying details. The April rally and subsequent fade was the latest — and almost certainly not the last — example of this pattern.

Investors who entered cannabis positions expecting rescheduling to be a single, transformative catalyst are recalibrating their timelines. Those who view it as one step in a multi-year normalization process are finding reasons for cautious optimism in the improving fundamental picture, even if the stock market hasn't yet rewarded that patience.

Find verified shops in your state through Budpedia's cannabis dispensary directory.